The addition of oxaliplatin to the Mayo Clinic schedule significantly increases its toxicity: A retrospective analysis of patients with advanced colorectal cancer

Clinical and Translational Oncology

Volumn 5, Issue 2, 2003, Pages 88-92

  Sarrió, Regina Gironés ^a   Muñoz, Eva Calabuig ^a   Urtasun, Jorge Aparicio ^a   Tendero, Pedro López ^a   Izquierdo, Ana Yuste ^a   Huerta, Ángel Segura ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Colorectal cancer; Metastatic disease; Oxaliplatin; Toxicity profile

Indexed keywords

EID: 33645789216     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Cvitkovic E, Bekradda M. Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol 1999;26:647-62.
2. Bleiberg H, de Gramont A. Oxaliplatin plus 5-Fluorouracil: Clinical experience in patients with Advanced Colorrectal Cancer. Semin Oncol 1998;25 (Suppl 5):32-5.
3. Ducreux M, Christophe L, Bekradda M, et al. Oxaliplatin for the treatment of advanced colorectal cancer: future directions. Semin Oncol 1998;25:47-53.
4. Comba AZ, Blajman C, Ricardet E, et al. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorrectal cancer patients. Eur J Cancer 2001;37:1006-13.
5. Lokich J, Ahlgren JD, Gallo JJ, et al. A prospective randomised comparison of continuous infusion of fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989;7:425-32.
6. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
7. Schmoll HJ, Köhne CH, Lorenz M, et al. Weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) with or without folinic acid (FA) versus bolus 5-FU-FA (NCCTG/Mayo) in advanced colorectal cancer: A randomised phase III study of the EORTC GITCCG and the AIO. Proc Am Soc Clin Oncol 2000;19:241a (Abstr 935).
8. The Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-8.
9. Maindrault-Goebel F, de Gramont A, Louvet C, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 2001;37:1000-5.
10. Cassidy J, Twelves C, Van Custem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566-75.
11. Rosati G, Rossi A, Tucci A, et al. Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. Ann Oncol 2001;12:669-74.
12. Bleiberg H, de Gramont A. Oxaliplatin plus 5-Fluorouracil: Clinical experience in patients with advanced colorectal cancer. Semin Oncol 1998;25 (Suppl 5):32-9.
13. Díaz-Rubio E, Sastre J, Zaniboni A. Oxaliplatin as a single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. Ann Oncol 1998;9:105-8.
14. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
15. Becouarn Y, Rougier P. Clinical Efficacy of Oxaliplatin Monotherapy: Phase II Trials in Advanced Colorectal Cancer. Semin Oncol 1998;25 (Suppl 5):23-31.
16. Raymond E, Chancy SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998;9:1053-71.
17. Büchele T, Balleisen L, Beck M, et al. Weekly high-dose (HD) 5-fluorouracil (5-FU) and folinic acid (FA) with addition of oxaliplatin (LOHP) after documented progression under high-dose infusional 5-FU/FA in patients (PTS) with advanced colorectal cancer (CRC). A multicenter phase II study. Abstract Book of International Colorectal Cancer Conference, Amsterdam, 1999;74.
18. Bohn U, Aguiar J, Aguiar D, et al. Adverse anaphylactoid reaction of oxaliplatin. Rev Oncol 2002;4:159-60.
19. Salinas P, Cortés-Funes H, Hitt Sabag R. Oxaliplatino y fiebre: presentación de 4 casos. Rev Oncol 2001;3:155-8.
20. Santini D, Tonini G, Salerno A, et al. Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol 2001;12:132-3.
21. Ulrich-Pur H, Fiebiger WCC, Schüll B, et al. Oxaliplatininduced fever and release of IL-6. Oncology 2000;59: 187-9.
22. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomised trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47.
23. Leichman CG, Fleming TR, Muggia F, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995;13:1303-11.
24. Tomiak A, Vincent M, Kochhar R, et al. Standard dose (Mayo Regimen) 5-fluorouracil and low dose folinic acid: prohibitive toxicity? Am J Clin Oncol 2000;23:94-8.
25. Scheithauer W, Kornek GV, Schuell B, et al. Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/ leucovorin-based chemotherapy. Ann Oncol 2001;12: 709-14.
26. Bertheault-Cvitkovic FB, Jami A, Ithzaki M, et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with metastatic colorectal cancer. J Clin Oncol 1996;14:2950-8.
27. Lévi F, Zidani R, Misset J-L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. For the International Organization for Cancer Chronotherapy. Lancet 1997;350:681-6.
28. Bismuth H, Adam R. Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. Semin Oncol 1998; 25 (Suppl 5): 40-6.